A landmark study presented at ESCMID Global 2025 reveals the devastating impact of antimicrobial resistance (AMR) on children's health. In 2022, over 3 million children worldwide died from antibiotic-resistant infections, highlighting the urgent need for global action.
Associate, David Hardstaff and Partner, John Binns at BCL Solicitors LLP, explain here how cannabis wonder child takes a knock in light of the European Commission’s ‘pause’ on CBD novel food applications mean for this booming industry.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Here, we learn how about a different kind of green crop that grows in Ireland and the journey of that from seed to shelf as part of the Greenheart CBD story.
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
In this interview, David Engel from Full Moon Investments in the U.S., charts the firm’s successful targeted investment strategy – informed by industry-leading experience and expertise – including comments on the CBD hemp and medical cannabis space.
Elixinol has launched a new UK range of blended, full-spectrum CBD capsules using six original combinations developed to support good health and wellbeing.
Dr Christian Löfke, responsible for research and product development at BioBloom, walks us through the rudiments of essential oils as a potential modulator of the endocannabinoid system.
In this final article of a series of five, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine when it comes to treating COVID-19.
